Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

TL;DR

  • Isomorphic Labs raised $5 billion in Series C funding.
  • The funding aims to advance drug candidates to clinical trials.
  • The company uses an AI drug-design engine building on DeepMind's AlphaFold.
  • Positive preclinical results have been observed in oncology and immunology.
  • Deals have been struck with Eli Lilly, Novartis, and Johnson & Johnson.
  • Demis Hassabis, founder and CEO, is now focusing full-time on Isomorphic Labs.
  • Existing investors include Alphabet's GV and Capital G, Thrive Capital, and others.